The rise in checkpoint inhibitor skin reactions may have an upside

Dermatologists are being urged to be vigilant for cutaneous immune‐related adverse effects (irAEs) that are becoming more apparent with the increasing use of immune checkpoint inhibitors (ICIs) in cancers. According to a Commentary in the British Journal of Dermatology, the PD‐1 inhibitors are now a first-line option in metastatic melanomas and also show significant potential ...

Already a member?

Enter your email to keep reading.